Retatrutide vs Wegovy (Semaglutide): How the Research Compares (2026)

Research note: Retatrutide is an investigational compound still in Phase 3 clinical trials and is not FDA-approved. Wegovy (semaglutide) is an FDA-approved prescription medication available only through a doctor. Research-grade “semaglutide” sold by peptide suppliers is a different regulatory category, intended for laboratory research only, and is not the same product as prescription Wegovy. This article compares the published clinical research on both compounds and is for educational purposes only — it is not medical advice.

What Is Retatrutide?

Retatrutide is Eli Lilly’s investigational “triple agonist,” activating the GLP-1, GIP, and glucagon receptors together, rather than targeting GLP-1 alone. It is currently being studied in the Phase 3 TRIUMPH trial program. In the TRIUMPH-1 trial (2,339 participants), 80-week results showed average weight loss of 17.6% on the 4mg dose, 23.7% on 9mg, and 25.0% on the 12mg dose, compared with 3.9% on placebo. Lilly’s FDA submission for retatrutide is estimated for late 2026 or early 2027, meaning it remains an investigational compound for the time being.

What Is Semaglutide (Wegovy)?

Semaglutide is a GLP-1 receptor agonist, and under the brand name Wegovy it is FDA-approved for chronic weight management at a 2.4mg dose. In the STEP 1 and STEP 3 trials, semaglutide 2.4mg produced average placebo-subtracted weight loss of 12.4% and 10.3% at 68 weeks. A higher, investigational 7.2mg dose tested in the STEP UP trial produced roughly 21% average weight loss over 72 weeks, with more than 90% of participants losing at least 5% of body weight.

Retatrutide vs Wegovy (Semaglutide): Comparison Table

Compound	Mechanism	Trial Weight Loss	Regulatory Status
Retatrutide	GLP-1 / GIP / Glucagon triple receptor agonist	Up to 25.0% (TRIUMPH-1, 12mg, 80 weeks)	Investigational — Phase 3, FDA submission expected late 2026/early 2027
Semaglutide (Wegovy, approved dose)	GLP-1 receptor agonist	10.3–12.4% placebo-subtracted (STEP 1/3, 2.4mg, 68 weeks)	FDA-approved prescription medication
Semaglutide (investigational 7.2mg)	GLP-1 receptor agonist	~21% (STEP UP, 72 weeks)	Investigational higher dose, not yet approved

The Core Difference: Single vs Triple Receptor Activity

The simplest way to frame the comparison: semaglutide targets one receptor pathway (GLP-1), while retatrutide targets three (GLP-1, GIP, and glucagon) at once. In head-to-head trial comparisons of weight loss percentages, retatrutide’s triple-agonist approach has shown larger average reductions at its higher doses than semaglutide’s approved 2.4mg dose — though semaglutide’s investigational 7.2mg dose narrows that gap considerably. Retatrutide is also the less-studied of the two, since it hasn’t completed the full regulatory review process semaglutide has already been through.

Bottom Line

Semaglutide (Wegovy) is the established, FDA-approved option with years of published outcome data and a defined prescribing pathway through a physician. Retatrutide is the newer, investigational triple-agonist showing strong trial results, but it hasn’t completed clinical review and isn’t an approved medication yet. Anyone considering either compound for personal use should discuss options with a licensed healthcare provider rather than relying on this article, which is intended for research and educational comparison only.

For more on retatrutide research, see our Retatrutide directory profile and Semaglutide directory profile, or join the discussion in our community forum.

Research Sources

Disclaimer: This article is for educational and informational purposes only. All linked listings are intended for laboratory research use only. Not for human or animal consumption. This content does not provide medical advice, diagnosis, or treatment. Some links may be affiliate links, meaning we may receive a commission at no additional cost to you.